(Q39460920)

English

Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy

scientific article published on 27 February 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Y Shibata

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

K Suzuki

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

S Arai

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Y Miyoshi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

S Umemoto

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

N Masumori

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

N Kamiya

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

T Ichikawa

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Y Kitagawa

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

A Mizokami

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Y Sugimura

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

N Nonomura

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

H Sakai

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

S Honma

14

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Y Kubota

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

27 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

505-511

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Steroid hormone analysis by tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Development of highly sensitive quantification method for testosterone and dihydrotestosterone in human serum and prostate tissue by liquid chromatography-electrospray ionization tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Changing therapeutic paradigms in castrate-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2047-2927.2013.00068.X

21 January 2018

Identifiers

10.1111/J.2047-2927.2013.00068.X

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

release_dwvhieipwjawnclrsph6y4ujjy

1 reference

https://api.fatcat.wiki/v0/release/dwvhieipwjawnclrsph6y4ujjy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39460920&oldid=1843504271"